Get the Stockscreener App
4.57
3.08%
-0.16
Sana Biotechnology Inc stock is traded at $4.57, with a volume of 1.09M.
It is down -3.08% in the last 24 hours and down -0.99% over the past month.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
See More
Previous Close:
$4.73
Open:
$4.7
24h Volume:
1.09M
Relative Volume:
0.22
Market Cap:
$1.22B
Revenue:
-
Net Income/Loss:
$-252.18M
P/E Ratio:
-4.3113
EPS:
-1.06
Net Cash Flow:
$-185.29M
1W Performance:
+12.63%
1M Performance:
-0.99%
6M Performance:
+17.85%
1Y Performance:
+6.61%
1-Day Range:
$4.545
$4.91
1-Week Range:
$4.01
$4.91
52-Week Range:
$1.26
$6.55
Sana Biotechnology Inc Stock (SANA) Company Profile
Name
Sana Biotechnology Inc
Sector
Industry
Phone
(206) 701-7914
Address
188 EAST BLAINE STREET, SUITE 400, SEATTLE
Compare SANA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
4.575 | 1.26B | 0 | -252.18M | -185.29M | -1.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.65 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.98 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
414.90 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.08 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.97 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Initiated | Wedbush | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Mar-18-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Mar-14-25 | Initiated | Jefferies | Buy |
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Nov-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-26-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-25-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Aug-14-23 | Initiated | TD Cowen | Market Perform |
| May-02-23 | Initiated | H.C. Wainwright | Neutral |
| Mar-01-21 | Initiated | BofA Securities | Buy |
| Mar-01-21 | Initiated | Goldman | Neutral |
| Mar-01-21 | Initiated | JP Morgan | Neutral |
| Mar-01-21 | Initiated | Morgan Stanley | Overweight |
View All
Sana Biotechnology Inc Stock (SANA) Latest News
Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Biotech company will stream its CEO's 2026 healthcare update live - Stock Titan
Sana Biotechnology (NASDAQ:SANA) Trading Up 7.4% Following Analyst Upgrade - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Price Target Raised to $7.00 at Bank of America - MarketBeat
Sana Biotechnology (NASDAQ:SANA) shaping Nasdaq 100 composition - Kalkine Media
Buybacks Report: Can Sana Biotechnology Inc stock maintain operating marginsJuly 2025 Big Picture & Daily Technical Stock Forecast Reports - moha.gov.vn
Big Picture: Can Sana Biotechnology Inc stock sustain market leadership - moha.gov.vn
Institutional Investors May Overlook Sana Biotechnology, Inc.'s (NASDAQ:SANA) Recent US$120m Market Cap Drop as Long-term Gains Remain Positive - 富途牛牛
Sana Biotechnology (NASDAQ:SANA) Shares Down 3.3%Time to Sell? - MarketBeat
Sana Biotech Stock Triples After Type 1 Diabetes Trial Wows Analysts: Retail Erupts In Excitement - MSN
Sana Biotechnology Showcases Successful In Vivo Gene Editing of Stem Cells in Nature Publication - Finviz
Sana Biotechnology showcases successful in vivo gene editing of stem cells in Nature publication - MSN
Seattle InnoSana and Bothell I Following up with ZenLedger - The Business Journals
Corient Private Wealth LLC Has $3.10 Million Stock Position in Sana Biotechnology, Inc. $SANA - MarketBeat
Sana Biotech Stock Jumps A Whopping 35% After Eric Jackson Calls It ‘Next 100-Bagger Platform’ - MSN
How Sana Biotechnology Inc. stock performs in weak economyJuly 2025 Technicals & Reliable Price Breakout Alerts - Улправда
Sana Biotechnology (NASDAQ:SANA) Upgraded at Wall Street Zen - MarketBeat
How resilient is Sana Biotechnology Inc. stock in market downturns2025 Top Decliners & Low Risk Entry Point Guides - Улправда
Can Sana Biotechnology Inc. stock maintain operating marginsWeekly Market Report & Stepwise Entry/Exit Trade Alerts - DonanımHaber
Can Sana Biotechnology Inc. stock sustain revenue growth2025 Technical Patterns & Real-Time Market Sentiment Reports - DonanımHaber
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 5.5%Here's What Happened - MarketBeat
CFO Wyrick Acquires 2,527 Of Sana Biotechnology Inc [SANA] - TradingView — Track All Markets
Sana Biotechnology, Inc. (SANA) insider details RSU vesting and stock sale - Stock Titan
Can Sana's Gene Editing Break New Ground In Treating Complex Diseases? - RTTNews
Marex Group plc Takes $10.42 Million Position in Sana Biotechnology, Inc. $SANA - MarketBeat
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Breakout Move: How interest rate cuts could boost Sana Biotechnology Inc stockQuarterly Profit Review & AI Powered Buy/Sell Recommendations - moha.gov.vn
Sana Biotechnology Reports Reduced Losses and Strong Liquidity - MSN
Sana Biotechnology (NASDAQ:SANA) Trading Up 8.8%Still a Buy? - MarketBeat
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Sana Biotechnology Stock: Soar or Sputter? - StocksToTrade
Sana Biotechnology (NASDAQ:SANA) Shares Down 5.9%Time to Sell? - MarketBeat
Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform - The Manila Times
Sana Biotechnology Announces Publication in Nature - GlobeNewswire
Sana Biotechnology (NASDAQ: SANA) Nature Biotech data show in vivo HSC gene editing - Stock Titan
Buyout Rumor: How Sana Biotechnology Inc stock performs in weak economyNew Guidance & Daily Profit Maximizing Trade Tips - moha.gov.vn
Sana (SANA) Surges 14.5% Ahead of Business Announcements - MSN
Is Sana Biotechnology's (SANA) SC451 Pivot Quietly Redefining Its Long-Term Platform Strategy? - simplywall.st
Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation - Quantisnow
Sana Biotechnology’s Surging Stock: Buy or Sell? - StocksToTrade
Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies - Quantisnow
Sana Biotechnology (NASDAQ:SANA) Trading Up 6.6%Should You Buy? - MarketBeat
Sana Biotechnology (SANA) Stock Analysis Report | Financials & Insights - Benzinga
Will Sana Biotechnology’s (SANA) Pipeline Focus Reveal Strategic Priorities in Diabetes and Autoimmune Innovation? - Yahoo Finance
Sana Biotechnology Beats Earnings Estimates, Prioritizes SC451 and CAR T - StocksToTrade
Sana Biotechnology Surges Amid Strong Q3 Earnings Performance - timothysykes.com
Sana Biotechnology (SANA): Assessing Valuation After Strong Year-to-Date Share Price Gains - Yahoo Finance
Sana Biotechnology (SANA): Evaluating Valuation After Recent Surge in Share Price - Sahm
10 Small Stocks with Mighty Gains - Insider Monkey
Sana Biotechnology (NASDAQ:SANA) Trading 12.8% HigherStill a Buy? - MarketBeat
Sana Biotechnology Inc Stock (SANA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sana Biotechnology Inc Stock (SANA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wyrick Susan D. | See Remarks |
Dec 13 '25 |
Option Exercise |
0.00 |
3,400 |
0 |
181,663 |
| Wyrick Susan D. | See Remarks |
Dec 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
180,828 |
| Wyrick Susan D. | See Remarks |
Jun 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
170,395 |
| Wyrick Susan D. | See Remarks |
Mar 07 '25 |
Option Exercise |
0.00 |
3,250 |
0 |
158,231 |
| Cassidy Bernard J | EVP & General Counsel |
Mar 07 '25 |
Option Exercise |
0.00 |
11,041 |
0 |
115,823 |
| Harr Steve | President & CEO |
Mar 07 '25 |
Option Exercise |
0.00 |
50,000 |
0 |
7,889,750 |
| Wyrick Susan D. | See Remarks |
Mar 02 '25 |
Option Exercise |
0.00 |
1,525 |
0 |
155,471 |
6.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):